- Home
- CCEC vs SPTX Comparison
CCEC vs SPTX Comparison
Compare CCEC & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | SPTX |
|---|---|---|
| Founded | 2007 | 2024 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2007 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CCEC | SPTX |
|---|---|---|
| Price | $21.51 | $18.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $25.83 | ★ $38.29 |
| AVG Volume (30 Days) | 3.4K | ★ 155.6K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.18 | N/A |
| Revenue Next Year | $36.89 | N/A |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.77 | $17.59 |
| 52 Week High | $24.00 | $28.38 |
Technical Indicators
Market Signals| Indicator | CCEC | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 44.86 |
| Support Level | $18.88 | $18.72 |
| Resistance Level | $21.69 | $22.75 |
| Average True Range (ATR) | 0.51 | 1.81 |
| MACD | -0.27 | -0.26 |
| Stochastic Oscillator | 37.26 | 32.71 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About SPTX Seaport Therapeutics Inc. Common Stock
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.